HIGHFIELDS CAPITAL MANAGEMENT LP - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 186 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2018. The put-call ratio across all filers is 0.99 and the average weighting 0.1%.

Quarter-by-quarter ownership
HIGHFIELDS CAPITAL MANAGEMENT LP ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2018$90,687,000
+218.6%
717,696
+111.6%
0.60%
+90.1%
Q2 2018$28,465,000
+36.4%
339,2320.0%0.31%
+65.6%
Q1 2018$20,870,000
+5.3%
339,2320.0%0.19%
+14.5%
Q4 2017$19,818,000
+0.7%
339,2320.0%0.16%
-2.9%
Q3 2017$19,689,000
-58.2%
339,232
-12.8%
0.17%
-51.3%
Q2 2017$47,124,000
+14.4%
389,232
+6.9%
0.35%
-8.6%
Q1 2017$41,195,000
-18.3%
364,232
-21.5%
0.38%
-8.6%
Q4 2016$50,439,000
+9.7%
464,232
+66.3%
0.42%
-3.0%
Q3 2016$45,959,000
-36.6%
279,232
-45.1%
0.43%
-31.8%
Q2 2016$72,515,000
+134.8%
508,232
+111.4%
0.63%
+119.4%
Q1 2016$30,883,000
+8.7%
240,392
+26.4%
0.29%
+17.6%
Q4 2015$28,410,000
+82.4%
190,226
+102.5%
0.24%
+78.8%
Q3 2015$15,579,000
+232.2%
93,926
+383.5%
0.14%
+226.2%
Q2 2015$4,689,000
-14.4%
19,4260.0%0.04%
-14.3%
Q1 2015$5,479,00019,4260.05%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q3 2018
NameSharesValueWeighting ↓
Sarissa Capital Management LP 635,300$53,308,00010.69%
Senvest Management, LLC 976,127$81,907,0005.65%
Melqart Asset Management (UK) Ltd 390,600$32,775,0002.80%
Asymmetry Capital Management, L.P. 25,918$2,175,0002.14%
Elk Creek Partners, LLC 386,397$32,423,0001.78%
BB BIOTECH AG 545,719$45,791,0001.32%
ALTRINSIC GLOBAL ADVISORS LLC 383,166$32,151,0001.27%
DLD Asset Management, LP 129,000$10,824,0000.82%
Opus Point Partners Management, LLC 3,998$335,0000.73%
Virtus ETF Advisers LLC 8,970$753,0000.67%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders